AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12797715 — intervention group
Group type: EXPERIMENTAL
Intervention: King's Health Questionnaire (KHQ)
Number of subjects: 1284
Study 9748928 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-occlusive dressing
Number of subjects: 0
Study 9748928 — intervention group
Group type: COMPARATOR
Intervention: Occlusive dressings
Number of subjects: 0
Study 7620184 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha)
Number of subjects: 170
Study 7620184 — intervention group
Group type: COMPARATOR
Intervention: Busulfan
Number of subjects: 170
Study 2096041 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic treatment (Opium and Raphanus)
Number of subjects: 600
Study 2096041 — intervention group
Group type: EXPERIMENTAL
Intervention: Opium + placebo
Number of subjects: 600
Study 2096041 — intervention group
Group type: COMPARATOR
Intervention: Two placebos
Number of subjects: 600
Study 2096041 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 600
Study 660514 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of diazepam
Number of subjects: 20
Study 660514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29412008 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: unenhanced CT with 100 kVp, 200 mA and contrast-enhanced CT with spectral CT mode using low dose protocols.
Number of subjects: 64
Study 29412008 — intervention group
Group type: COMPARATOR
Intervention: Group B: conventional helical scanning with 120 kVp, auto mA for noise index of 12 HU for both unenhanced and contrast-enhanced CT.
Number of subjects: 64
Study 29412008 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: average radiation dose of 2.64 mSv.
Number of subjects: 64
Study 29412008 — intervention group
Group type: COMPARATOR
Intervention: Group B: average radiation dose of 6.18 mSv.
Number of subjects: 64
Study 29412008 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: total iodine intake of 13.5g.
Number of subjects: 64
Study 29412008 — intervention group
Group type: COMPARATOR
Intervention: Group B: total iodine intake of 21g.
Number of subjects: 64
Study 27615044 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial muscle exercise program including facial massage (20 minutes a day, 3 times a week for two weeks)
Number of subjects: 70
Study 27615044 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 70
Study 27615044 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial muscle exercise program including facial massage
Number of subjects: 70
Study 24269096 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flexion TKA
Number of subjects: 122
Study 24269096 — intervention group
Group type: COMPARATOR
Intervention: Standard TKA
Number of subjects: 122
Study 22334808 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-bilevel device
Number of subjects: 51
Study 22334808 — intervention group
Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 51
Study 22334808 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Auto-bilevel and CPAP)
Number of subjects: 51
Study 20862934 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture on different acupoints in combination with rehabilitation (group A)
Number of subjects: 90
Study 20862934 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture in combination with rehabilitation training (group B)
Number of subjects: 90
Study 20862934 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation training only (group C)
Number of subjects: 90
Study 18849625 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-ml volume of anesthetic solution
Number of subjects: 108
Study 18849625 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-ml volume of anesthetic solution
Number of subjects: 108
Study 18849625 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-ml volume of anesthetic solution
Number of subjects: 108
Study 18849625 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 108
Study 15803078 — intervention group
Group type: EXPERIMENTAL
Intervention: Head rotated to the left during rear-end impact
Number of subjects: 20
Study 15803078 — intervention group
Group type: EXPERIMENTAL
Intervention: Head rotated to the right during rear-end impact
Number of subjects: 20
Study 15803078 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing levels of acceleration (4.4, 7.9, 10.9, and 13.1 m/s)
Number of subjects: 20
Study 11792336 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management training (1.5-hour weekly class)
Number of subjects: 94
Study 11792336 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 94
Study 11792336 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (3 times per week for 4 months)
Number of subjects: 94
Study 10069869 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma duration (years)
Number of subjects: 1041
Study 7578657 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral mCPP (0.5 mg/kg)
Number of subjects: 12
Study 7578657 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous mCPP (0.1 mg/kg over 20 min)
Number of subjects: 12
Study 7578657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2267922 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone and oral prednisolone for 5 days
Number of subjects: 38
Study 2267922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 509022 — intervention group
Group type: EXPERIMENTAL
Intervention: 92 dBA noise
Number of subjects: 0
Study 509022 — intervention group
Group type: COMPARATOR
Intervention: 75 dBA quiet
Number of subjects: 0
Study 509022 — intervention group
Group type: EXPERIMENTAL
Intervention: 92 dBA noise with suppressed rehearsal
Number of subjects: 0
Study 509022 — intervention group
Group type: COMPARATOR
Intervention: 75 dBA quiet with suppressed rehearsal
Number of subjects: 0
Study 31930308 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate statin group (re‐initiation on the first postoperative day)
Number of subjects: 301
Study 31930308 — intervention group
Group type: COMPARATOR
Intervention: Late statin group (re‐initiation on the fifth postoperative day)
Number of subjects: 301
Study 30621831 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 67
Study 30621831 — intervention group
Group type: COMPARATOR
Intervention: Non-CBT-I (control group)
Number of subjects: 67
Study 28872734 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon (50-65 vol%) plus sevoflurane
Number of subjects: 40
Study 28872734 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane alone
Number of subjects: 40
Study 26197184 — intervention group
Group type: EXPERIMENTAL
Intervention: H7N9 vaccine without adjuvant (15 µg hemagglutinin)
Number of subjects: 980
Study 26197184 — intervention group
Group type: EXPERIMENTAL
Intervention: H7N9 vaccine with AS03 adjuvant (15 µg hemagglutinin)
Number of subjects: 980
Study 26197184 — intervention group
Group type: EXPERIMENTAL
Intervention: H7N9 vaccine with MF59 adjuvant (15 µg hemagglutinin)
Number of subjects: 980
Study 26197184 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 AS03-adjuvanted formulations
Number of subjects: 980
Study 23660315 — intervention group
Group type: EXPERIMENTAL
Intervention: MYCu IUD
Number of subjects: 2000
Study 23660315 — intervention group
Group type: COMPARATOR
Intervention: TCu380A IUD
Number of subjects: 2000
Study 21368590 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine in HIV-infected pregnant women
Number of subjects: 38
Study 21368590 — intervention group
Group type: COMPARATOR
Intervention: Influenza vaccine in uninfected pregnant women
Number of subjects: 38
Study 19792840 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical evidence-based decision portals
Number of subjects: 0
Study 19792840 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardization of study-reporting criteria
Number of subjects: 0
Study 16876891 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 542
Study 16876891 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 542
Study 16876891 — intervention group
Group type: COMPARATOR
Intervention: MT
Number of subjects: 542
Study 15204893 — intervention group
Group type: EXPERIMENTAL
Intervention: Life Review Therapy (3 one-hour sessions)
Number of subjects: 14
Study 15204893 — intervention group
Group type: COMPARATOR
Intervention: Neutral video with follow-up discussion (control group)
Number of subjects: 14
Study 11535325 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanamivir 20 mg daily for 14 days
Number of subjects: 40
Study 11535325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9753701 — intervention group
Group type: EXPERIMENTAL
Intervention: lormetazepam
Number of subjects: 18
Study 9753701 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 7757392 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Skills Reinforcement (ISR) method
Number of subjects: 93
Study 7757392 — intervention group
Group type: COMPARATOR
Intervention: Lecture method (comparison group)
Number of subjects: 93
Study 3058133 — intervention group
Group type: EXPERIMENTAL
Intervention: Muroctasin (MDP-Lys(L18)) at a dose of 200 micrograms, administered subcutaneously starting on day 4 after chemotherapy for 10 days
Number of subjects: 20
Study 3058133 — intervention group
Group type: COMPARATOR
Intervention: Control cycle (standard chemotherapy protocol)
Number of subjects: 20
Study 3058133 — intervention group
Group type: EXPERIMENTAL
Intervention: Muroctasin
Number of subjects: 20
Study 3058133 — intervention group
Group type: COMPARATOR
Intervention: Control cycle
Number of subjects: 20
Study 29392846 — intervention group
Group type: EXPERIMENTAL
Intervention: High flow nasal cannulae (HFNC) therapy
Number of subjects: 92
Study 29392846 — intervention group
Group type: COMPARATOR
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 92
Study 28086934 — intervention group
Group type: EXPERIMENTAL
Intervention: Real electroacupuncture/moxibustion treatments
Number of subjects: 30
Study 28086934 — intervention group
Group type: COMPARATOR
Intervention: Sham electroacupuncture/moxibustion treatments
Number of subjects: 30
Study 26331843 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonist exenatide
Number of subjects: 48
Study 23549993 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 45
Study 23549993 — intervention group
Group type: EXPERIMENTAL
Intervention: Portland Cement (PC)
Number of subjects: 45
Study 23549993 — intervention group
Group type: COMPARATOR
Intervention: Calcium Hydroxide (CH)
Number of subjects: 45
Study 21352431 — intervention group
Group type: EXPERIMENTAL
Intervention: 24% sucrose solution
Number of subjects: 40
Study 21352431 — intervention group
Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 40
Study 18311768 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 47
Study 18311768 — intervention group
Group type: COMPARATOR
Intervention: Control group (no psychological intervention)
Number of subjects: 47
Study 17207378 — intervention group
Group type: EXPERIMENTAL
Intervention: COMBI (sulphasalazine, methotrexate, hydroxychloroquine, and prednisolone)
Number of subjects: 195
Study 17207378 — intervention group
Group type: COMPARATOR
Intervention: SINGLE (initially sulphasalazine with or without prednisolone)
Number of subjects: 195
Study 17207378 — intervention group
Group type: EXPERIMENTAL
Intervention: COMBI
Number of subjects: 195
Study 17207378 — intervention group
Group type: COMPARATOR
Intervention: SINGLE
Number of subjects: 195
Study 14586044 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol
Number of subjects: 30
Study 10922432 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonist therapy (diltiazem and verapamil)
Number of subjects: 817
Study 8868770 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 1531673 — intervention group
Group type: EXPERIMENTAL
Intervention: Cl2MDP (2‐dichloromethylene bisphosphonate), 600 mg in 500 mL of normal saline
Number of subjects: 24
Study 1531673 — intervention group
Group type: COMPARATOR
Intervention: Placebo (500 mL of normal saline)
Number of subjects: 24
Study 1531673 — intervention group
Group type: EXPERIMENTAL
Intervention: Cl2MDP
Number of subjects: 24
Study 1531673 — intervention group
Group type: COMPARATOR
Intervention: Cl2MDP and Placebo
Number of subjects: 24
Study 6436855 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural psychotherapy from a nurse therapist
Number of subjects: 50
Study 6436855 — intervention group
Group type: COMPARATOR
Intervention: Routine care from their general practitioner (GP)
Number of subjects: 50
Study 30665438 — intervention group
Group type: EXPERIMENTAL
Intervention: Integral movement therapy, 20 supervised sessions over 10 weeks, twice per week, approximately 1 hour per session.
Number of subjects: 0
Study 30665438 — intervention group
Group type: COMPARATOR
Intervention: Conventional local movement therapy, 20 supervised sessions over 10 weeks, twice per week, approximately 1 hour per session.
Number of subjects: 0
Study 30400924 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) supplement for 6 weeks
Number of subjects: 73
Study 30400924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 26967321 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion pretreatment
Number of subjects: 16
Study 26967321 — intervention group
Group type: COMPARATOR
Intervention: MDMA (125 mg)
Number of subjects: 16
Study 26967321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 24947817 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 1200
Study 24947817 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 1200
Study 24947817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1200
Study 24947817 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine and Tamsulosin
Number of subjects: 1200
Study 22701382 — intervention group
Group type: COMPARATOR
Intervention: BUV40 (backup rate of 40 bpm)
Number of subjects: 28
Study 22701382 — intervention group
Group type: EXPERIMENTAL
Intervention: OVP (overdrive ventricular pacing at 20 bpm above mean nocturnal heart rate)
Number of subjects: 28
Study 22701382 — intervention group
Group type: COMPARATOR
Intervention: Comparison between BUV40 and OVP in patients without heart failure
Number of subjects: 28
Study 22701382 — intervention group
Group type: COMPARATOR
Intervention: Comparison between BUV40 and OVP in patients with heart failure
Number of subjects: 28
Study 22701382 — intervention group
Group type: COMPARATOR
Intervention: Central AHI in patients without HF
Number of subjects: 28
Study 22701382 — intervention group
Group type: COMPARATOR
Intervention: Central AHI in patients with HF
Number of subjects: 28
Study 22701382 — intervention group
Group type: COMPARATOR
Intervention: Obstructive AHI in patients without HF
Number of subjects: 28
Study 22701382 — intervention group
Group type: COMPARATOR
Intervention: Obstructive AHI in patients with HF
Number of subjects: 28
Study 19539384 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg daily
Number of subjects: 42
Study 19539384 — intervention group
Group type: COMPARATOR
Intervention: allopurinol 300 mg daily
Number of subjects: 42
Study 17586712 — intervention group
Group type: EXPERIMENTAL
Intervention: Cantilever resin‐bonded fixed partial dentures
Number of subjects: 60
Study 17586712 — intervention group
Group type: COMPARATOR
Intervention: Conventional removable partial dentures
Number of subjects: 60
Study 15848559 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified release tacrolimus (MR tacrolimus) once daily (qD)
Number of subjects: 70
Study 15848559 — intervention group
Group type: COMPARATOR
Intervention: Prograf twice a day
Number of subjects: 70
Study 12487387 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir-containing regimen
Number of subjects: 0
Study 9729588 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (240 mg/day)
Number of subjects: 11
Study 9729588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 8129130 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask insertion
Number of subjects: 20
Study 8129130 — intervention group
Group type: COMPARATOR
Intervention: Tracheal intubation
Number of subjects: 20
Study 2808215 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 0.25 g
Number of subjects: 6
Study 2808215 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 0.5 g
Number of subjects: 6
Study 2808215 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 1.0 g
Number of subjects: 6
Study 2808215 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem with probenecid
Number of subjects: 6
Study 2808215 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (general)
Number of subjects: 6
Study 1173199 — intervention group
Group type: EXPERIMENTAL
Intervention: Obex-LA (105 mg sustained action)
Number of subjects: 9
Study 1173199 — intervention group
Group type: COMPARATOR
Intervention: Obex (35 mg non-sustained action)
Number of subjects: 9
Study 1173199 — intervention group
Group type: EXPERIMENTAL
Intervention: Obex-LA
Number of subjects: 9
Study 1173199 — intervention group
Group type: COMPARATOR
Intervention: Obex
Number of subjects: 9
Study 7013721 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral mexiletine (200 mg 4 times daily)
Number of subjects: 40
Study 7013721 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral disopyramide (100 mg 4 times daily)
Number of subjects: 40
Study 31002110 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% CFP without PB
Number of subjects: 22
Study 31002110 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% CaLS to the 3% SO diets
Number of subjects: 22
Study 31002110 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% CFP diets with 2% Ben
Number of subjects: 22
Study 31002110 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% SO with 0.21 to 0.56% CaLS
Number of subjects: 22
Study 31002110 — intervention group
Group type: EXPERIMENTAL
Intervention: Diets containing less than 2.86% SO with 0.5% CaLS
Number of subjects: 22
Study 31002110 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 to 2.50% CFP diets without CaLS
Number of subjects: 22
Study 31002110 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing CaLS levels more than 0.38%
Number of subjects: 22
Study 29504795 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Number of subjects: 148
Study 27969025 — intervention group
Group type: EXPERIMENTAL
Intervention: BREATHE: Stress Management for Nurses program
Number of subjects: 104
Study 27969025 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study 24395850 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 111
Study 24395850 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 111
Study 22681782 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-item PCS-D anxiety measure
Number of subjects: 450
Study 22681782 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-factor model
Number of subjects: 450
Study 22681782 — intervention group
Group type: EXPERIMENTAL
Intervention: Subscales of the 3-factor model
Number of subjects: 450
Study 19054012 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg ghrelin
Number of subjects: 10
Study 19054012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 17876852 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide spray (1-2 sprays, maximum of 4 times per day)
Number of subjects: 17
Study 17876852 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide spray
Number of subjects: 17
Study 17876852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 15107190 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine in addition to standard treatment
Number of subjects: 68
Study 15107190 — intervention group
Group type: COMPARATOR
Intervention: Standard detoxification protocol
Number of subjects: 68
Study 11579987 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression of obsessional thoughts
Number of subjects: 219
Study 11579987 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression of positive thoughts
Number of subjects: 219
Study 11579987 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression of neutral thoughts
Number of subjects: 219
Study 11579987 — intervention group
Group type: COMPARATOR
Intervention: No suppression (control group)
Number of subjects: 219
Study 9608880 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine eye drops 0.025%
Number of subjects: 24
Study 9608880 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine eye drops 0.05%
Number of subjects: 24
Study 9608880 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine eye drops 0.1%
Number of subjects: 24
Study 9608880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7740443 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatan sulphate 200 mg once daily
Number of subjects: 153
Study 7740443 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatan sulphate 200 mg twice daily
Number of subjects: 153
Study 7740443 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatan sulphate 300 mg twice daily
Number of subjects: 153
Study 7740443 — intervention group
Group type: COMPARATOR
Intervention: Standard prophylactic agents
Number of subjects: 153
Study 2736440 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% glucose polymer solution, 0.5 L ingested 10 min before the game and at half-time (Experimental Team - ET)
Number of subjects: 10
Study 2736440 — intervention group
Group type: COMPARATOR
Intervention: Placebo, equal volumes ingested at the same times (Control Team - CT)
Number of subjects: 10
Study 46510 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte transfusion therapy (1 or more bags of granulocyte-rich plasma)
Number of subjects: 41
Study 46510 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte transfusion therapy (1 bag of granulocyte-rich plasma)
Number of subjects: 41
Study 46510 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte transfusion from normal donors
Number of subjects: 41